An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer

Article Oncology

The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2-) advanced/metastatic breast cancer

Aditya Bardia et al.

Summary: This study evaluated the safety and efficacy of GDC-0810 in patients with ER+ advanced/MBC. The results showed that GDC-0810 was safe and tolerable, and had preliminary anti-tumor activity in these patients.

BREAST CANCER RESEARCH AND TREATMENT (2023)

Add to Collection

Article Oncology

[18F]FDG and [18F]FES PET/CT Imaging as a Biomarker for Therapy Effect in Patients with Metastatic ER plus Breast Cancer Undergoing Treatment with Rintodestrant

Ramsha Iqbal et al.

Summary: The purpose of this study was to investigate the use of [18F]-fluorodeoxyglucose ([18F]FDG) and [18F]-fluoro-17(3-estradiol ([18F]FES) PET/CT imaging in patients with metastatic ER-positive breast cancer undergoing treatment with rintodestrant. The study found that absence of ER expression on [18F]FES PET is a predictor for no response to rintodestrant. [18F]FES uptake during treatment and at time of progression is useful to monitor the effect of therapy and continued mode of action of SERDs.

CLINICAL CANCER RESEARCH (2023)

Add to Collection

Meeting Abstract Oncology

SERENA-4: A Phase III comparison of AZD9833 (camizestrant) plus palbociclib, versus anastrozole plus palbociclib, for patients with ER-positive/HER2-negative advanced breast cancer who have not previously received systemic treatment for advanced disease

Fabrice Andre et al.

CANCER RESEARCH (2022)

Add to Collection

Meeting Abstract Oncology

SERENA-6: A Phase III study to assess the efficacy and safety of AZD9833 (camizestrant) compared with aromatase inhibitors when given in combination with palbociclib or abemaciclib in patients with HR+/HER2-metastatic breast cancer with detectable ESR1m who have not experienced disease progression on first-line therapy

Francois-Clement Bidard et al.

CANCER RESEARCH (2022)

Add to Collection

Article Oncology

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

Francois-Clement Bidard et al.

Summary: Elacestrant, a novel oral selective estrogen receptor degrader, demonstrated significant improvement in progression-free survival in patients with pretreated estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer, including those with ESR1 mutations, with manageable adverse events.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib versus letrozole plus palbociclib for previously untreated ER+/HER2-advanced breast cancer

Aditya Bardia et al.

Summary: This study aims to evaluate the efficacy and safety of Amcenestrant in combination with Palbociclib as first-line therapy for estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast cancer. Pre-/postmenopausal women and men with no prior systemic therapy are enrolled and randomized to receive either Amcenestrant plus Palbociclib or Letrozole plus Palbociclib. The primary endpoint is progression-free survival, and the key secondary endpoint is overall survival, along with safety, pharmacokinetics, and quality of life assessments.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2022)

Add to Collection

Article Multidisciplinary Sciences

Real-world data of fulvestrant as first-line treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer

I. Blancas et al.

Summary: The study evaluated the effectiveness of fulvestrant as first-line treatment for ER-positive ABC in real-world settings. Results showed that fulvestrant can prolong progression-free survival and is well tolerated, with patients who had an ECOG score of 0 at the start of treatment showing better clinical benefit and overall survival. The study's findings are in line with randomized clinical trials, demonstrating the continued clinical benefits of fulvestrant for postmenopausal women with ER-positive ABC.

SCIENTIFIC REPORTS (2021)

Add to Collection

Article Oncology